The purpose of this study is to compare the accuracy of an ultrasound device FibroScan® with SmartExam®, in relation to the FibroScan® device, which is the current standard, used in clinical care to diagnose and screen for certain types of liver diseases.
The FibroScan® device is widely used to assess the health of a person’s liver. It measures liver stiffness and liver fat to help identify people with chronic liver disease i.e., liver disease that has been present for many years.
Over time there have been technical advancements with ultrasound devices, and newer or upgraded devices/software are now available. For this reason, the Sponsor is conducting a study to understand how these two devices compare in their ability to evaluate the condition of the liver.
Participants will be asked to be participate in one study visit. The study will involve coming to the study site, which is the Pfizer Innovation Research Laboratory at 610 Main Street, in Cambridge, Massachusetts. The study visit will last approximately 90-120 minutes.
You will be asked to fast (water permitted) for a minimum of 4 hours prior to the study visit. During the study visit you will have 2 exams with the Fibroscan® ultrasound device and 2 exams with the SmartExam®.
If you are eligible to participate in the study, you may receive compensation for taking part in this study. If you are withdrawn or withdraw from the study for whatever reason, you may be eligible to receive compensation for the portions of the study you have completed. For each visit you make to our study site, you will also be reimbursed to cover reasonable expenses (such as parking) that you have as a result of taking part in this study.